Giuseppe Benagiano1, Carlo Bastianelli, Manuela Farris. 1. University 'la Sapienza', Postgraduate School of Gynaecology and Obstetrics, Policlinico Umberto I degrees , Viale Regina Margherita 245, 00161 Roma, Italy.
Abstract
BACKGROUND: A number of synthetic steroids are capable of modulating progesterone receptors with a spectrum of activities ranging from pure antagonism to a mixture of agonism and antagonism. The best known of these are mifepristone (RU 486), asoprisnil (J 867), onapristone (ZK 98299), ulipristal (CDB 2914), Proellex() (CDB 4124), ORG 33628 and ORG 31710. OBJECTIVE: Outside reproduction selective modulators of progesterone receptors have been under investigation for a large variety of indications, for example in oncology as adjuvants in breast, cervical, endometrial, ovarian and prostate cancer, as well as inoperable meningioma and leiomyosarcoma. In addition, they have been used as antiglucocorticoids. It is therefore useful to review the results obtained in these conditions. METHODS: A careful evaluation of existing major review papers and of recently published articles was carried out for the indications under review, focusing not only on mifepristone but also on those other selective modulators of progesterone receptors for which data are available. RESULTS/ CONCLUSIONS: In preliminary studies selective modulators of progesterone receptors had some activity on a number of neoplasias. Their antiglucocorticoid activity has been tested with some success in Cushing's syndrome, several psychiatric conditions (e.g., mood disorders and Alzheimer's disease) and acute renal failure. Finally they are being used in a gene regulator system.
BACKGROUND: A number of synthetic steroids are capable of modulating progesterone receptors with a spectrum of activities ranging from pure antagonism to a mixture of agonism and antagonism. The best known of these are mifepristone (RU 486), asoprisnil (J 867), onapristone (ZK 98299), ulipristal (CDB 2914), Proellex() (CDB 4124), ORG 33628 and ORG 31710. OBJECTIVE: Outside reproduction selective modulators of progesterone receptors have been under investigation for a large variety of indications, for example in oncology as adjuvants in breast, cervical, endometrial, ovarian and prostate cancer, as well as inoperable meningioma and leiomyosarcoma. In addition, they have been used as antiglucocorticoids. It is therefore useful to review the results obtained in these conditions. METHODS: A careful evaluation of existing major review papers and of recently published articles was carried out for the indications under review, focusing not only on mifepristone but also on those other selective modulators of progesterone receptors for which data are available. RESULTS/ CONCLUSIONS: In preliminary studies selective modulators of progesterone receptors had some activity on a number of neoplasias. Their antiglucocorticoid activity has been tested with some success in Cushing's syndrome, several psychiatric conditions (e.g., mood disorders and Alzheimer's disease) and acute renal failure. Finally they are being used in a gene regulator system.
Authors: Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Bert Kazemier; Rolien Bosch; Ross McGuire; Rita Azevedo; Hans Hamersma; Koen Dechering; Arthur Oubrie; Marcel van Duin; Jacob de Vlieg Journal: J Biol Chem Date: 2012-04-25 Impact factor: 5.157
Authors: Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Koen Dechering; Tsang Wai Lam; Angus R Brown; Niall M Hamilton; Olaf Nimz; Rolien Bosch; Ross McGuire; Arthur Oubrie; Jacob de Vlieg Journal: J Biol Chem Date: 2011-08-17 Impact factor: 5.157
Authors: Hai-Bing Zhou; Jae Hak Lee; Christopher G Mayne; Kathryn E Carlson; John A Katzenellenbogen Journal: J Med Chem Date: 2010-04-22 Impact factor: 7.446
Authors: Carolyn L Westhoff; Hua Guo; Zhong Wang; Hanina Hibshoosh; Margaret Polaneczky; Malcolm C Pike; Richard Ha Journal: Breast Cancer Res Treat Date: 2022-01-11 Impact factor: 4.624
Authors: Xia Luo; Ping Yin; John S Coon V; You-Hong Cheng; Ronald D Wiehle; Serdar E Bulun Journal: Fertil Steril Date: 2010-01-08 Impact factor: 7.329
Authors: Roisin O'Cearbhaill; Qin Zhou; Alexia Iasonos; Robert A Soslow; Mario M Leitao; Carol Aghajanian; Martee L Hensley Journal: Gynecol Oncol Date: 2009-11-24 Impact factor: 5.482
Authors: Chelsea R Tieszen; Alicia A Goyeneche; BreeAnn N Brandhagen; Casey T Ortbahn; Carlos M Telleria Journal: BMC Cancer Date: 2011-05-27 Impact factor: 4.430